Mirum Pharmaceuticals, Inc.

Mirum Pharmaceutical Misses on Revenue, Stock Down 2.59%

Mirum Pharmaceutical reported a larger-than-expected loss per share, which was a positive surprise compared to consensus expectations. However, the stock fell 2.59% following the earnings report, likely due to the lack of revenue information and no guidance updates. Investors may be concerned about the company's future performance given the current market challenges highlighted by management.